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Background: Early detection of decreased glomerular filtration rate (GFR) in dogs is challenging.
Current methods are insensitive and new biomarkers are required.
Objective: To compare overall diagnostic performance of serum symmetric dimethylarginine
(SDMA) and serum cystatin C to serum creatinine, for detection of decreased GFR in clinically
stable dogs, with or without chronic kidney disease (CKD).
Animals: Ninety-seven client-owned dogs: 67 dogs with a diagnosis or suspicion of CKD and
30 healthy dogs were prospectively included.
Methods: Prospective diagnostic accuracy study. All dogs underwent physical examination, sys-
temic arterial blood pressure measurement, urinalysis, hematology and blood biochemistry anal-
ysis, cardiac and urinary ultrasound examinations, and scintigraphy for estimation of glomerular
filtration rate (mGFR). Frozen serum was used for batch analysis of SDMA and cystatin C.
Results: The area under the curve of creatinine, SDMA, and cystatin C for detection of an
mGFR <30.8 mL/min/L was 0.98 (95% confidence interval [CI], 0.93-1.0), 0.96 (95% CI,
0.91-0.99), and 0.87 (95% CI, 0.79-0.93), respectively. The sensitivity of both creatinine and
SDMA at their prespecified cutoffs (115 μmol/L [1.3 mg/dL] and 14 μg/dL) for detection of an
abnormal mGFR was 90%. The specificity was 90% for creatinine and 87% for SDMA. When
adjusting the cutoff for cystatin C to correspond to a diagnostic sensitivity of 90% (0.49 mg/L),
specificity was lower (72%) than that of creatinine and SDMA.
Conclusions and Clinical Importance: Overall diagnostic performance of creatinine and SDMA
for detection of decreased mGFR was similar. Overall diagnostic performance of cystatin C was
inferior to both creatinine and SDMA.
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1 | INTRODUCTION
A clinical diagnosis of chronic kidney disease (CKD) in dogs can be
established on the basis of structural damage to the kidneys, or
decreased renal function, or both. Although the kidneys are important
for many aspects of homeostasis, the glomerular filtration rate (GFR)
often is used as an indicator of global renal function.1 An early diagnosis
of progressive CKD provides an opportunity to apply renoprotective
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measures that might benefit affected dogs.2 In clinically and hemody-
namically stable dogs, a decrease in GFR is most likely a consequence
of CKD. Calculation of GFR in dogs requires multiple blood samplings
(plasma clearance methods) or special equipment and expertise (scintig-
raphy). Glomerular filtration rate therefore most often is estimated indi-
rectly using circulating biomarkers, such as creatinine.1,3 The use of
serum creatinine concentration compared to a broad population-based
reference interval is suboptimal, but robust alternatives are lacking.1
The absence of an accurate, simple, and minimally invasive marker of
GFR is a limiting factor in clinical nephrology research and clinical prac-
tice, and new, more precise, alternatives are continuously sought.
Symmetric dimethylarginine (SDMA) is an amino acid released from
cells during protein degradation, which was first isolated in human urine
in 1970.4 Clearance of SDMA is mainly accomplished by glomerular fil-
tration.5 A meta-analysis of 18 diagnostic studies showed a strong cor-
relation between SDMA and different markers of renal function in
people.6 Commercially available SDMA assays for use in dogs recently
were introduced, and serum SDMA has since been increasingly used as
an indirect marker of GFR. Unfortunately, the 2 published diagnostic
studies do not present data that can be used to determine diagnostic
performance of SDMA as a marker of GFR in dogs.7,8 Regardless,
SDMA is thought to represent, and is advertised as, a sensitive indicator
of decreased GFR in dogs.9
Cystatin C, a low-molecular-weight (13 kDa) cysteine protease, is
produced at a stable rate by all nucleated cells and cleared by glomer-
ular filtration.10,11 This protein was first proposed as an endogenous
circulating indirect marker of GFR in people in 1985,12,13 and is now
routinely used in equations for calculation of estimated GFR (eGFR)
either alone or together with creatinine.14,15 In people, addition of
cystatin C to creatinine-based eGFR equations improves accuracy of
estimates.16,17 In dogs, cystatin C has been evaluated as a GFR marker
using different analytical methods and study designs, and is consid-
ered potentially useful.18–25 More work is needed to confirm the diag-
nostic value of cystatin C as a marker of decreased GFR in dogs.26
Our aim was to compare the overall diagnostic performance of
serum SDMA and serum cystatin C to serum creatinine for detection
of decreased GFR in clinically stable dogs with a diagnosis or strong
suspicion of CKD. Our hypothesis was that overall diagnostic perfor-
mance would be similar for all 3 markers. A secondary aim was to eval-
uate if combining either SDMA, cystatin C, or both, with creatinine
increases sensitivity or specificity or both for detection of decreased
GFR, compared to creatinine alone.
2 | MATERIAL AND METHODS
2.1 | Study design and study population
This prospective diagnostic accuracy study was performed at the Swed-
ish University of Agricultural Sciences, Uppsala. All owners approved
and signed an informed consent form. Client-owned dogs of any breed
and age with a previous CKD diagnosis, or for which the attending clini-
cian had a suspicion of CKD, were included. Participating dogs were
referred, or presented as primary patients, to the University Animal
Hospital (2012-2016). The diagnosis of CKD, defined as structural or
functional abnormalities of 1 or both kidneys that had persisted for at
least 3 months, had been made previously in many dogs, using standard
methods (compatible clinical signs, results of urinalysis, hematological
and biochemical analyses, morphological renal abnormalities detected
by urinary tract ultrasound examination, or some combination of these).
Exclusion criteria were presence of other systemic or organ-related dis-
eases or chronically administered medications (except PO glucosamino-
glycan supplements, sodium pentosane polysulfate injections, angiotensin
converting enzyme [ACE] inhibitors or phosphate binding agents [PBAs]).
If the dog was receiving an ACE inhibitor or PBA, the drug was withdrawn
1 week before inclusion, and reintroduced after study participation. Renal
diets were allowed. Healthy student, client, and staff-owned dogs of any
breed and age also were prospectively included. Inclusion of dogs was
performed at preplanned hospital visits, designated for study inclusion
only, to ensure clinical stability. At the day of enrollment into the study,
dogs underwent physical examination, repeated blood pressure measure-
ments, collection of venous blood and urine, echocardiographic examina-
tion, abdominal ultrasound examination of the entire urinary tract, and a
scintigraphic examination for calculation of individual kidney mGFR. Dogs
with CKD were classified according to International Renal Interest Society
(IRIS) classification system into stage 1 through 4, based on stable serum
creatinine concentration.
2.2 | Systemic arterial blood pressure measurement
Indirect blood pressure measurements were performed by oscillome-
try (High Definition Oscillometry, S+B medVET, Germany; iE33, Phi-
lips Ultrasound, Bothell, Washington) after rest and accommodation
to the premises. The cuff was put on the base of the tail and pressure
was recorded with the dog standing, either on the floor or on the
examination table, depending on where the dog seemed to be most
comfortable. A minimum of 5 measurements were recorded for each
dog, more in case of presumably incorrect measurements (such as a
presumably incorrect heart rate registration on the device, a >20%
variation in systolic blood pressure [SBP] among measurements, or an
obviously distressed animal).
2.3 | Abdominal ultrasound and echocardiography
Complete upper and lower urinary tract ultrasound examinations were
conducted by experienced diagnostic imagers at the University Animal
Hospital diagnostic imaging clinic. Dogs were non-sedated and exam-
ined in dorsal recumbency during the procedure, which was performed
according to a predefined protocol. Echocardiographic examinations of
all dogs were performed by experienced ultrasonographers to exclude
primary heart disease because such disease might affect renal function
and extracellular fluid volume.
2.4 | Blood and urine examinations
Blood was drawn from the cephalic vein into tubes without anticoagu-
lant and tubes containing EDTA. Samples were transferred to the clinical
chemistry laboratory at the University Animal Hospital for immediate
hematological (CBC including manual differential cell count) and
biochemical analysis (urea, creatinine, alkaline phosphatase, alanine
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aminotransferase, total calcium [Ca], inorganic phosphate [P], sodium
[Na], potassium [K], chloride, cholesterol, C-reactive protein, total pro-
tein, albumin, and fibrinogen). After analyses, serum and EDTA plasma
were frozen (−20) in aliquots and subsequently (within 24 hours) trans-
ferred to storage at −70. For most dogs, urine was obtained by cysto-
centesis at the time of the abdominal ultrasound examination. If
cystocentesis was not possible, fresh spontaneously voided urine was
collected. Urine was aliquoted, and 5-10 mL (depending on the total
volume of urine obtained) was immediately used for analysis (dipstick
and sediment examinations, specific gravity [USG], urine protein-to-
creatinine ratio [UPC], and aerobic culture).
2.5 | Glomerular filtration rate and plasma volume
estimation by scintigraphy
Estimation of individual kidney GFR was performed using renal scintig-
raphy (plasma volume method) according to hospital routine. The exam-
inations were performed as previously described,27 by an experienced
diagnostic imager, blinded to results of the index tests (creatinine,
SDMA, and cystatin C). Results were normalized to an estimation of
plasma volume.28 The predefined cutoff for a decreased total (left +
right kidney) mGFR by plasma volume method in the University Animal
Hospital was 30.8 mL/min/L.27,28 A second, less conservative, cutoff
for decreased mGFR was defined, based on the results of mGFR in the
healthy dogs of the present study. This cutoff was set at a level that
resulted in an mGFR within normal limits in approximately 95% of
healthy dogs.
2.6 | Biomarker analysis
Serum creatinine concentration was determined using an enzymatic
method (Architect c4000, Abbott, Abbott Park, Illinois). The prede-
fined reference interval was 46-115 μmol/L (0.5-1.3 mg/dL).
Frozen (−70) serum was sent to Idexx Laboratories GmbH, Lud-
wigsburg, Germany, and analyzed in batch with a commercially available
method for quantification of SDMA, in 2017 (IDEXX SDMA Test, Idexx
Laboratories GmbH). The predefined reference interval was 0-14 μg/dL.
Frozen (−70C) serum was transported to the Department of Clini-
cal Chemistry, University Hospital, Uppsala, Sweden, and analyzed in
batch in 2017. Cystatin C measurement was performed using a particle-
enhanced immunoturbidimetric assay (PETIA, [Gentian, Moss, Norway],
on Architect c8200 [Abbott, Abbott Park, Illinois]), previously validated
for use in dogs.24
Laboratory staffs at each site were blinded to results of all other
variables.
2.7 | Statistical analyses
Statistical calculations were performed using commercially available
software programs (JMP Pro 11, SAS Institute, Cary, North Carolina)
(MedCalc Version 17.9.7 64-bit). A P-value of <.05 was considered sig-
nificant. Medians and interquartile ranges (IQRs) were used to describe
distribution of continuous variables. Data were assessed graphically for
normality, and non-normally distributed variables were log-transformed.
In the statistical analyses of the present study, results from the plasma
volume method were used as a reference because this method is
thought to be less dependent on hydration status of the dog.27–30
Spearman’s correlation between integral and plasma volume methods
of GFR estimation (r) was 0.8. Univariate linear regression (continuous
variables) and Wilcoxon rank sum test (categorical variables) were per-
formed to assess associations among creatinine, SDMA, and cystatin C,
respectively, and the following variables: age, body weight (BW), sex,
mGFR, PCV, SBP, P, Ca, albumin, Na, K, USG, and storage time. Multi-
ple regression analyses were performed in a backward stepwise man-
ner. All variables that were linearly correlated with creatinine, SDMA,
or cystatin C, respectively, with a P value <.2, were included. Thereaf-
ter, the variable with the highest P value was removed in each step until
all remaining variables were significant. For regression analyses, resid-
uals were plotted and visually inspected.
Receiver operating characteristic (ROC) curve analysis was per-
formed at the 2 different cutoffs for mGFR (<30.8 and <37 mL/min/L,
respectively) in order to evaluate overall diagnostic performance of all
3 biomarkers at 2 different levels of GFR impairment.
Sensitivity, specificity and positive and negative likelihood ratios
(LRs) were calculated for each biomarker at their prespecified clinically
used cutoffs, and if necessary, specificity recalculated with cut points
that achieved the same sensitivity for each of the diagnostic tests. For
cystatin C, the cutoff that corresponded to the same sensitivity as that
of creatinine and SDMA was chosen for these calculations, because
the use of the “optimal” cutoff value for cystatin C identified in the
present study possibly could inflate diagnostic accuracy results. Inter-
val LRs were constructed by examining ROC tables and choosing rele-
vant cutoffs in an attempt to maximize the clinical utility of results.
The diagnostic efficacy of the model obtained from the multiple
regression analysis to predict the presence of decreased mGFR was
further evaluated by the use of ROC curves at the 2 different cutoffs
for mGFR. The ROC curves were evaluated using area under the curve
(AUC) and calculating 95% confidence interval (CI), and differences
were tested using the method by Hanley and McNeil.
Recursive partitioning was used to create decision trees for opti-
mal clinical use of recorded variables in order to evaluate GFR.
Usefulness of cystatin C and SDMA for improvement of diagnos-
tic performance in a selected population (dogs that were falsely cate-
gorized regarding mGFR, positively or negatively, by creatinine) was
assessed by evaluating results of the SDMA and cystatin C analysis
for each individual dog. The usefulness of creatinine and cystatin C as
adjuncts to SDMA similarly was assessed.
The Wilcoxon rank sum test was used to compare results of mGFR,
SDMA, and cystatin C among the following subgroups: healthy dogs and
dogs in IRIS stages 1, 2, and 3 CKD. Dogs in group 4 were excluded from
these analyses because too few were available. In these analyses, Bon-
ferroni correction was applied and P < .01 was considered significant.
3 | RESULTS
3.1 | Study population
A total of 105 dogs were enrolled in the study, but only 97 dogs had all
requisite data and were included in the analysis. Reasons for excluding
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the remaining 8 dogs are given in Figure 1. No adverse events
were recorded during collection of study data. The study population
comprised 12 mixed breed dogs, 6 Labradors, 6 Golden Retrievers,
5 Boxers, 4 Border Collies, and ≤3 individuals of 51 other breeds. Of
these dogs, 30 were healthy. Fourteen dogs were not conclusively
diagnosed with CKD, because of absence of confirmed structural or
functional renal abnormalities. Median (IQR) age of all included dogs
was 5.2 (2.5-8.7) years, median BW 20.0 (IQR, 11.5-27.3) kg, and
median mGFR 43 (IQR, 25-51) mL/min/L. Urine was obtained by
cystocentesis in 90 dogs and by spontaneous voiding in 7 dogs. Clini-
cal and laboratory characteristics of included dogs are presented in
Table 1. Creatinine, SDMA, and cystatin C all were nonlinearly nega-
tively associated with mGFR (Figure 2A-C). The additional more con-
servative mGFR cutoff was set to <37 mL/min/L.
3.2 | Comparison among subgroups
Results of mGFR, SDMA, and cystatin C were different between
healthy dogs and dogs in IRIS stages 1, 2, and 3 (Figure 3A-C).
3.3 | Univariate and multiple regression analyses
Serum creatinine concentration increased with decreasing mGFR (R2 =
0.62; P < .001), PCV (R2 = 0.48; P < .001), USG (R2 = 0.14; P < .001) and
albumin (R2 = .06; P = .02) and with increasing P (R2 = 0.24; P < .001),
Ca (R2 = 0.19; P < .001), K (R2 = 0.10; P = .002), and age (R2 = 0.62;
P < .001) in the univariate analyses. The variables mGFR, age, BW, P, PCV,
albumin, SBP, Ca, Na, K, and USG were included in the multiple regression
analysis.MeasuredGFR, BW, PCV, and Pwere the variables independently
associatedwith creatinine (R2adj = 0.74; P < .001).
Serum SDMA concentration increased with decreasing mGFR (R2 =
0.62; P < .001), PCV (R2 = 0.46; P < .001), USG (R2 = 0.21; P < .001)
and albumin (R2 = 0.17; P < .001), and with increasing P (R2 = 0.26;
P < .001), Ca (R2 = 0.13; P < .001), and K (R2 = 0.11; P = .001) in the
univariate analyses. The variables mGFR, age, P, PCV, albumin, SBP,
Ca, K, USG, and storage time were included in the multiple regression
analysis. Measured GFR, P, albumin, and USG were the variables inde-
pendently associated with SDMA (R2adj = 0.71; P < .001).
Cystatin C concentration increased with decreasing mGFR (R2 =
0.46; P < .001), PCV (R2 = 0.38; P < .001), USG (R2 = 0.23; P < .001)
and albumin (R2 = 0.06; P = .01), and with increasing age (R2 = 0.16; P <
.001), P (R2 = 0.16; P < .001), Ca (R2 = 0.16; P < .001), K (R2 = 0.14;
P = .002), and BP (R2 = 0.10; P = .004) in the univariate analyses. The
variables mGFR, age, P, PCV, albumin, SBP, Ca, K, and USG were
included in the multiple regression analysis. Measured GFR, age, PCV,
Ca, and USG were the variables independently associated with cystatin
C (R2adj = 0.62; P < .001).
3.4 | Overall diagnostic assessment
Log creatinine was linearly associated with mGFR (R2 = 0.62, Figure 2C).
The AUC of creatinine for detection of mGFR <30.8 mL/min/L was 0.98
CKD diagnosis
(n=59)
Inconclusive
(n= 14)
Healthy dogs
(n=30)
• Physical examination
• Blood pressure 
• Complete blood count
• Biochemistry panel
• Urinalysis
• Cardiac and urinary tract 
ultrasound
SDMA, Cystatin C
(n=97)
Clinically stable dogs
(n=103)
Prior diagnosis or suspicion 
of CKD (n=75)
mGFR measurement
(n=100)
Excluded dogs: 
Owner withdrawal (n=2)
Excluded dogs (with CKD diagnosis):
Insufficient serum volume for analysis of 
SDMA (n=3)
Excluded dogs (with CKD diagnosis):
Scintigraphy not performed (n=3)
FIGURE 1 Flowchart of the study including reasons for exclusion of 8 dogs. CKD, chronic kidney disease; mGFR, measured glomerular filtration
rate; SDMA, symmetric dimethylarginine
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(95% CI, 0.93-1.0) and that for detection of mGFR <37 mL/min/L was
0.94 (95% CI, 0.87-0.98; Figure 4).
Log SDMA was linearly associated with mGFR (R2 = 0.62,
Figure 2D). The AUC of SDMA for detection of mGFR <30.8 mL/min/L
was 0.96 (95% CI, 0.91-0.99) and that for detection of an mGFR
<37 mL/min/L was 0.94 (95% CI, 0.87-0.98). No difference in overall
diagnostic performance was detected between creatinine and SDMA
at either cutoff of mGFR (Figure 4).
TABLE 1 Dog characteristics and clinical variables
Healthy
(n = 30)
Inconclusive
(n = 14)
CKD stage 1
(n = 26)
CKD stage 2
(n = 12)
CKD stage 3
(n = 12)
CKD stage 4
(n = 3)
Creatinine (μmol/L) 83 (75-98) 87 (71-106) 85 (75-104) 145 (137-171) 217 (187-281) 573
Creatinine (mg/dL) 0.9 (0.8-1.1) 1.0 (0.8-1.2) 1.0 (0.8-1.2) 1.6 (1.5-1.9) 2.4 (2.1-3.2) 6.5
Age (y) 4.9 (3.0-7.8) 3.4 (2.4-7.0) 5.1 (1.7-7.6) 3.5 (1.2-11) 6.9 (4.0-10.5) 10.8
BW (kg) 20 (16-25) 22 (14-34) 18 (8.6-28) 19 (9-25) 18 (8-29) 45
mGFR (mL/min/L) 51 (47-61) 46 (40-56) 47 (36-50) 21 (15-26) 13 (6-17) 5
SDMA (μg/dL) 11 (9-12) 12 (9-14) 13 (11-14) 21 (17-28) 28 (27-33) 55
Cystatin (mg/L) 0.31 (0.26-0.41) 0.48 (0.37-0.62) 0.42 (0.37-0.64) 0.57 (0.49-0.85) 1.38 (0.97-2.56) 3.69
SBP (mm Hg)a 127 (114-140) 133 (124-157) 137 (125-157) 135 (121-168) 145 (130-176)
Values are given as median (interquartile range).
Abbreviations: BW, body weight; CKD, chronic kidney disease; inconclusive, dogs with a suspicion of CKD but no final diagnosis by CKD definition; mGFR,
measured glomerular filtration rate; SDMA, symmetric dimethylarginine; stage, International Renal Interest Society stage of CKD.
aSystolic blood pressure (SBP) was available for only 84 dogs, including 2 dogs in CKD stage 4. Therefore, no value is given for stage 4 dogs.
FIGURE 2 Original plots of A, creatinine; B, symmetric dimethylarginine (SDMA); and C, cystatin C versus measured glomerular filtration rate
(mGFR) in 97 dogs. Linear associations between D, log creatinine; E, log SDMA; and F, log cystatin C and mGFR in 97 dogs
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Log cystatin C was linearly associated with mGFR (R2 = 0.46,
Figure 2E). The AUC of cystatin C for detection of an mGFR
<30.8 mL/min/L was 0.87 (95% CI, 0.79-0.93) and that for detec-
tion of an mGFR <37 mL/min/L was 0.83 (95% CI, 0.74-0.90).
Cystatin C was significantly inferior to creatinine at both mGFR cut-
offs but inferior to SDMA only at the higher cutoff (<37 mL/min/L,
Figure 4).
The cutoffs identified in the ROC curve analysis as optimal (tak-
ing into account both sensitivity and specificity) in this population
of dogs, to detect an mGFR <30.8 mL/min/L, were 126 μmol/L
(1.4 mg/dL) for creatinine, 16 μg/dL for SDMA, and 0.47 mg/L for
cystatin C.
3.5 | Diagnostic performance of serum markers at
prespecified and defined cutoffs
The sensitivity of creatinine and SDMA at their prespecified cutoffs
(115 μmol/L [1.3 mg/dL] and 14 μg/dL, respectively) for detection of
an abnormal (<30.8 mL/min/L) mGFR was the same (90%) in the dogs
of the present study. The specificity was 90% for creatinine and 87%
for SDMA. A “defined” cutoff for cystatin C that corresponded to the
same level of sensitivity (90%) therefore was chosen (0.49 mg/L),
which corresponded to a specificity of 75%. Sensitivity, specificity,
positive and negative LRs for creatinine, SDMA, and cystatin C at their
predefined/defined cutoffs for detection of decreased (<30.8 mL/min/L)
mGFR are presented in Table 2. Interval LRs for all 3 markers are pre-
sented in Table 3.
3.6 | Usefulness of SDMA and cystatin C as adjunct
tests to creatinine
The combination of creatinine and SDMA for detection of decreased
mGFR in a multiple regression model resulted in an adjusted R2 of
0.67 and an AUC of 0.98. For the combination of creatinine and
cystatin C, adjusted R2 was 0.65 and the AUC was 0.99. When creati-
nine, SDMA, and cystatin C all were used to construct a model,
adjusted R2 was 0.68 and AUC was 0.99.
The resultant decision tree when every clinical variable was used in
the partition model to predict if mGFR was abnormal (<30.8 mL/min/L)
or not included creatinine and cystatin C only. The resultant decision
tree was identical when only creatinine, SDMA, and cystatin C initially
were entered into the model (Figure 5).
Ten (10%) dogs were falsely categorized by creatinine at its pre-
specified cutoff with regard to mGFR (<30.8 mL/min/L) status. Seven
results were falsely positive (serum creatinine concentration ranging
from 117 to 136 μmol/L [1.3-1.5 mg/dL]) and 3 were falsely negative
(serum creatinine concentration ranging from 100 to 105 μmol/L
[1.1-1.2 mg/dL]). Seven of these 10 dogs were correctly classified by
SDMA at its prespecified cutoff. Eight of them were correctly classi-
fied by cystatin C at its “defined” cutoff of 0.49 mg/L.
FIGURE 4 Receiver operator characteristic curve analysis.
Comparison of overall diagnostic value of creatinine, symmetric
dimethylarginine (SDMA), and cystatin C for detection of A, measured
glomerular filtration rate (mGFR) <30.8 mL/min/L and B, mGFR
<37 mL/min/L in 97 dogs. There was no difference between overall
performance of creatinine and SDMA at either cutoff for mGFR
(P = .37 and .70, respectively)
FIGURE 3 A, Measured glomerular filtration rate (GFR); B, symmetric
dimethylarginine (SDMA); and C, cystatin C concentrations in
30 healthy dogs and 50 dogs with chronic kidney disease, in
international renal interest society (IRIS) stages 1-3. The top, bottom,
and middle lines through each box correspond to the 75th percentile,
the median, and the 25th percentile, respectively. The whiskers
extend from the bottom 10th percentile to the top 90th percentile.
Asterisks indicate significant differences in biomarker concentrations
between groups (P < .01)
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Twelve (12%) dogs were falsely categorized by SDMA at its pre-
specified cutoff with regard to mGFR (<30.8 mL/min/L) status. Nine
results were falsely positive (serum SDMA concentration ranging from
15 to 19 μg/dL) and 3 were falsely negative (serum SDMA concentra-
tion ranging from 12 to 14 μg/dL). Nine of these dogs were correctly
classified by creatinine at its prespecified cutoff. Eight of them were
correctly classified by cystatin C at its “defined” cutoff of 0.49 mg/L.
4 | DISCUSSION
In this diagnostic accuracy study, overall performance of creatinine
and SDMA as markers of decreased mGFR was the same. Perfor-
mance of cystatin C on the other hand was inferior to both creatinine
and SDMA. In the subpopulation of dogs for which creatinine (at its
predefined cutoff) was falsely positive or negative, both SDMA and
cystatin C appeared to be of value as adjunct markers for interpreta-
tion of mGFR status. Similarly, for the subpopulation of dogs for
which SDMA (at its predefined cutoff) was falsely positive or nega-
tive, creatinine and cystatin C both were considered valuable adjunct
markers for mGFR interpretation.
Overall diagnostic performance (AUC) of SDMA as a marker of
decreased mGFR was the same as that of creatinine in our study.
Symmetric dimethylarginine currently is marketed as a more sensitive
marker of decreased GFR than creatinine. Consequently, and because
of current uncertainty regarding what exactly constitutes a decreased
GFR, we chose to evaluate overall diagnostic performance of creati-
nine, SDMA and cystatin C at 2 different mGFR cutoffs. As expected,
overall diagnostic performance of all 3 markers was lower at the
higher mGFR cutoff, but again, the performances of creatinine and
SDMA were not different from each other. Our conclusion is that cre-
atinine and SDMA have similar overall diagnostic value for detection
TABLE 2 Sensitivity, specificity, and likelihood ratios at prespecified single cutoffs
Biomarker Predefined cutoff value Sensitivity (%) Specificity (%) LR+ LR−
Creatinine 115 μmol/L(1.3 mg/dL) 90 (73-98) 90 (80-96) 8.7 (4.3-17.8) 0.12 (0.04-0.34)
SDMA 14 μg/dL 90 (73-98) 87 (76-94) 6.8 (3.6-12.6) 0.12 (0.04-0.35)
Cystatin C 0.49a mg/L 90 (73-98) 74 (61-83) 3.4 (2.2-5.1) 0.14 (0.05-0.41)
Values are given with 95% confidence interval (CI) in brackets.
Abbreviations: LR−, negative likelihood ratio; LR+, positive likelihood ratio; SDMA, symmetric dimethylarginine.
aDefined cutoff value, that is, the cutoff for cystatin C that corresponded to the same sensitivity (90%) as that of creatinine and SDMA in the present
study.
TABLE 3 Proposed interval likelihood ratios (for detection of mGFR
<30.8 mL/min/L)
Biomarker
Serum
concentration
mGFR
decreased
(number
of dogs)
mGFR
normal
(number
of dogs)
Interval
likelihood
ratios
Creatinine μmol/L
(mg/dL)
>127 (1.4) 26 1 61
101-127 (1.1-1.4) 2 14 0.33
≤100 (<1.1) 1 53 0.04
SDMA μg/dL >16 25 1 61
14-16 1 8 0.29
≤13 3 59 0.05
Cystatin C mg/L >0.91 18 1 42
0.47-0.91 9 18 1.1
≤0.46 2 49 0.14
Abbreviations: mGFR, measured glomerular filtration rate; SDMA, sym-
metric dimethylarginine.
Dogs with suspected 
decreased GFR
Abnormal mGFR: 29
Normal mGFR: 68
Creatinine ≥127 (≥1.4) 
Abnormal mGFR: 26
Normal mGFR: 1 
Creatinine <127 (<1.4)
Abnormal mGFR: 3
Normal mGFR: 67
Creatinine ≥100 (≥1.1)
Abnormal mGFR: 3
Normal mGFR: 15
Cystatin C <0.51
Abnormal mGFR: 4
Normal mGFR: 1
Cystatin C ≥0.51
Abnormal mGFR: 22
Normal mGFR: 0
Creatinine <100 (<1.1)
Abnormal mGFR: 0
Normal mGFR: 52 
Cystatin C<0.51
Abnormal mGFR: 0
Normal mGFR: 12 
Cystatin C≥0.51
Abnormal mGFR: 3
Normal mGFR: 3
FIGURE 5 Fig 5. Partition modelling. Resultant decision tree when every clinical variable was entered into the model to predict if mGFR was
abnormal (< 30.8 mL/min/L) or not. An identical decision tree resulted if only creatinine, SDMA and cystatin C were entered into the model.
Cystatin C units: mg/L. Creatinine units: μmol/L. The equivalent of 127 μmol/L is 1.4 mg/dL and the equivalent of 100 μmol/L is 1.1 mg/dL
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of decreased GFR. The exact sensitivity and specificity of these con-
tinuous biomarkers depend on which cutoff is chosen.
In our study, the single cutoff for an optimal combination of sensi-
tivity and specificity of SDMA for detection of a decreased mGFR was
16 μg/dL. If a higher sensitivity is preferred, the cutoff of 14 μg/dL
could be maintained, but would result in a higher number of false posi-
tives compared to a cutoff of 16 μg/dL. We propose the use of inter-
val LRs when interpreting results of this SDMA test (Table 3). These
interval LRs were not validated in a separate cohort of dogs, which
should be performed in future studies. Likelihood ratios are factors
used to modify the pretest probability of disease, preferably with the
use of a Fagan nomogram.31 An LR >10 or <0.1 provides information
that modifies the pretest probability in a highly useful way.32
Overall diagnostic performance of cystatin C, when measured
using a PETIA, was inferior to both creatinine and SDMA. Cystatin C
however was considered useful for clinical GFR estimation based on
results from the partition model (decision tree) and when evaluations
of assay results in individual dogs were reviewed. Therefore, this
assay, when used as an adjunct test to creatinine and interpreted
using the decision tree or the interval LRs proposed here, might prove
to be clinically useful. Additional studies however are needed to vali-
date these interval LRs as well as the decision tree, and to further
evaluate cystatin C as a marker of decreased GFR in clinical situations.
The cutoff for creatinine of 115 μmol/L (1.3 mg/dL), which is
used clinically at our hospital for detection of decreased GFR, resulted
in the same sensitivity and specificity as did the SDMA test in our
population of dogs. If a high sensitivity for creatinine (or SDMA or any
other continuous biomarker) is desired and the cutoff is lowered, the
specificity invariably will decrease and, at some point, the test will no
longer be clinically useful because of an unacceptably low specificity.
According to our results (ROC analysis), the optimal single cutoff for
creatinine in our dog population was 126 μmol/L (1.4 mg/dL). If a high
sensitivity is desired and the cutoff is set at 115 μmol/L (1.3 mg/dL),
some healthy large breed dogs will be categorized as azotemic. As an
alternative, 2 different reference intervals, 1 for small and 1 for larger
dogs, could be considered, although this also would not completely
account for the influence of breed and muscle mass. A third option is
to interpret serum creatinine concentration using interval LRs. In the
present study, we suggest interval LRs that could be of use in serum
creatinine concentration interpretation. Validation of these interval
LRs should be carried out in future studies. The exact cutoffs for dif-
ferent intervals of LR also might differ among different creatinine
assays.33 Either way creatinine is interpreted, the signalment of the
dog must be taken into consideration in the diagnostic thought
process.
Variables (other than mGFR) that were independently associated
with the 3 biomarkers in the multiple regression analyses were those
associated with renal function (PCV, Ca, P, albumin, and USG). The
only 2 exceptions were the independent association between BW and
creatinine, and that between age and cystatin C. This finding was
expected because the dependence of serum creatinine concentration
on muscle mass is known.34–36 Body weight in this population of dogs
depends on breed as well. Some large breeds (such as the Greyhound,
represented by 3 individuals in our study) have higher serum concen-
trations of creatinine than do dogs of other breeds, possibly despite
higher GFR.37–40 An age dependence of cystatin C also has been
described previously in dogs.20,24 Age has, however, not been consid-
ered to influence cystatin C concentrations in humans or cats.41–44
Not all of the dogs that had a tentative diagnosis of CKD could be
given a final CKD diagnosis based on GFR measurement. The reasons
for including dogs in the study regardless of a diagnosis of CKD were
2-fold. First, this group of dogs more closely represents the population
in which these tests are performed clinically, namely dogs that are sus-
pected of having decreased renal function, rather than dogs that
already have been given a diagnosis of decreased renal function. Sec-
ond, avoidance of a case-control scenario in diagnostic accuracy stud-
ies decreases the risk of spectrum bias (exaggeration of diagnostic
accuracy).45 As is the case for most continuous biomarkers, the diag-
nostic performance of a biomarker of decreased GFR is best in dogs
with advanced disease, but the test becomes less efficient as GFR
approaches normal. Therefore, inclusion of individuals with suspected
minor decreases in GFR (such as the inconclusive dogs and many of
the stage 1 CKD dogs in our study) is important in a diagnostic accu-
racy study evaluating performance of a biomarker of decreased GFR.
Regardless of how GFR is estimated or calculated, it is necessary to
clinically ascertain if decreased GFR is a consequence of prerenal, renal,
or postrenal problems, and if it is acutely or chronically decreased. If
GFR is chronically (>3 months) decreased because of a renal disorder,
this finding represents 1 of several criteria on which to base a clinical
diagnosis of CKD.46 However, a diagnosis of CKD also can be made on
the basis of presence of structural abnormalities of 1 or both kidneys.46
In these cases, GFR sometimes is normal, and the disease might also be
nonprogressive (ie, clinical signs may not ever develop). Thus, it is
important to acknowledge that abnormal GFR and CKD are 2 separate,
but often coexistent, entities.
4.1 | Limitations
It is impossible to directly measure GFR, therefore it is instead esti-
mated by use of filtration markers. Clearance, or in case of scintigra-
phy, renal uptake, of a marker is used to estimate GFR. There is a
large variation in reported measurements of GFR in dogs.34,47–53 Ref-
erence ranges differ with methodology and choice of normalization
variable, but also among studies using similar methods. In a previous
study using scintigraphy, most of the variability in GFR was a result of
variation among dogs, less to day-to-day variability, and very little var-
iation was due to the GFR estimation technique.28 Regardless, in our
study the same methodology was used in all dogs, and therefore
should have equal consequences for creatinine, SDMA, and cystatin
C. Additionally, the cutoff for decreased GFR likely differs among sub-
populations of dogs (eg, regarding age, breed, and BW).54 Although
mGFR has been shown to decrease with increasing BW in healthy
dogs,54 in our study, no significant effect of BW on mGFR was seen in
the healthy, inconclusive or stage 1 dogs (data not shown). This find-
ing might be due to the fact that all dogs but 2 in the previously men-
tioned groups weighed <40 kg. Hydration status also influences GFR
measurements.55 The plasma volume method is less dependent on
hydration status of the animal and therefore was chosen for statistical
analyses.27,29,30,56 Also, dogs were included at a time point when they
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were considered to be clinically stable, in order to further minimize
any influence of hydration status.
The laboratory used for analysis of SDMA in our study recently
changed the cutoff for SDMA to 16 μg/dL for dogs under the age of
12 months.9 This change in protocol was not accounted for in the sta-
tistical calculations. Two of the dogs <1 year of age (6 and 11 months
old, respectively) with normal GFR in our study had serum SDMA con-
centrations of 15 μg/dL. However, 1 of these dogs was diagnosed
with renal cysts and had low normal GFR (38 mL/min/L). Taking this
change into account, the number of dogs falsely classified by SDMA
decreased from 12 to 10, which is identical to the number of dogs
falsely classified by creatinine. Furthermore, removing these 2 young
dogs from the AUC calculations resulted in an AUC for SDMA of 0.97
instead of 0.96, which was not significantly different from the AUC of
creatinine when the 2 dogs were removed (0.98).
Frozen (−70C) samples obtained between 2012 and 2016 were
sent for batch analysis of cystatin C and SDMA in early 2017. Concen-
trations of SDMA (analyzed by liquid chromatography-mass spectrome-
try) have shown stability in samples stored for 7 and 14 days at 20
and 4, respectively, and after 3 freeze-thaw cycles.7 Stability of cysta-
tin C concentrations in human serum measured by the assay used in
our study was confirmed after storage up to 1 month at 2C-8C.57
Stability of SDMA and cystatin C in canine serum stored at −70 for
several years, however, has not been investigated. Storage time there-
fore was included as an explanatory variable in the univariate regression
analyses. For SDMA, storage time subsequently also was included in
the multiple regression analysis, but was not retained in the final model.
5 | CONCLUSION
In our study, the overall diagnostic performance of creatinine and
SDMA as markers of decreased mGFR in clinically stable dogs was
found to be similar. Performance of cystatin C was inferior to that of
creatinine and SDMA. However, use of either SDMA or cystatin C or
both as adjuncts to creatinine may provide additional value for diagno-
sis of decreased GFR. This information may have an impact on the way
dogs with suspected decreased GFR are investigated and managed.
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